Hospitalist Doctors in Winchester, VA Accepting Medicare

5 Hospitalist doctors found. Showing 1 - 5

Akua Safo, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-4334

Ramez Issam Emile Alyacoub, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8000

Corissa Nicole Hockman, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8000    Fax: 540-836-3286

Gaurav T Parikh, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-2270    Fax: 540-536-7847

Jeyandra Selvam, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-2270    Fax: 540-536-7847

News Archive

Insufficient evidence on prostate cancer radiation treatment

Reuters: "There is not enough evidence to sort out the effect of various radiation treatments for prostate cancer patients, especially newer, so-called focused radiation, an advisory panel told the U.S. Medicare agency on Wednesday.

New York Times: AIDS drug program has growing waiting list

The New York Times: "The weak economy is crippling the government program that provides life-sustaining antiretroviral drugs to people with H.I.V. or AIDS who cannot afford them. Nearly 1,800 have been relegated to rapidly expanding waiting lists that less than three years ago had dwindled to zero. ...

Biological explanation for psychopathy

Professor Declan Murphy and colleagues Dr Michael Craig and Dr Marco Catani from the Institute of Psychiatry at King's College London have found differences in the brain which may provide a biological explanation for psychopathy. The results of their study are outlined in the paper 'Altered connections on the road to psychopathy', published in Molecular Psychiatry.

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.

Read more Medical News

› Verified 6 days ago